Pfizer Inc. (NYSE:PFE – Get Free Report)’s stock price traded down 0.2% during trading on Tuesday . The stock traded as low as $25.74 and last traded at $25.87. 6,391,758 shares were traded during trading, a decline of 85% from the average session volume of 42,236,316 shares. The stock had previously closed at $25.91.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the stock. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday. Twelve investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $36.88.
Pfizer Stock Down 0.8 %
The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm’s 50-day moving average is $27.27 and its 200 day moving average is $28.84. The stock has a market cap of $145.47 billion, a price-to-earnings ratio of 71.69, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61.
Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the prior year, the business posted $1.14 earnings per share. Pfizer’s revenue for the quarter was down 41.3% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Pfizer
Large investors have recently made changes to their positions in the business. Wellington Management Group LLP boosted its stake in shares of Pfizer by 4.9% in the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock valued at $6,886,849,000 after purchasing an additional 11,099,024 shares during the period. Moneta Group Investment Advisors LLC boosted its stake in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after purchasing an additional 160,963,976 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Pfizer by 8.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company’s stock valued at $2,985,783,000 after purchasing an additional 8,473,686 shares during the period. Morgan Stanley boosted its stake in shares of Pfizer by 0.4% in the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after purchasing an additional 348,628 shares during the period. Finally, Norges Bank bought a new position in Pfizer during the 4th quarter valued at $2,129,927,000. Institutional investors and hedge funds own 68.36% of the company’s stock.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.